Dashboard
Manage Tickers

AGIO


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 12:09:16

hc-wainwright--co-reiterates-buy-on-agios-pharmaceuticals-maintains-56-price-target
HC Wainwright & Co. Reiterates Buy on Agio...
09/04/2025 16:04:25

HC Wainwright & Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and maintains $56 pri...

fda-delays-decision-on-agios-pharmaceuticals-blood-disorder-drug-for-expanded-use
FDA Delays Decision On Agios Pharmaceutica...
09/04/2025 14:49:53

Agios' Pyrukynd FDA review for thalassemia delayed to Dec. 7, 2025, after REMS submission addressing potential liver injury...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/04/2025 12:08:12

agios-pharmaceuticals-announces-pdufa-goal-date-for-pyrukynd-extended-by-three-months-to-dec-7
Agios Pharmaceuticals Announces PDUFA Goal...
09/04/2025 11:45:50

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
08/21/2025 17:35:27

saudi-food-and-drug-authority-approves-agios-pyrukynd-for-adults-with-thalassemia
Saudi Food And Drug Authority Approves Agi...
08/04/2025 20:22:10

First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines ProgramAgios partnered...

agios-pharmaceuticals-says-it-is-aware-of-the-securities-analyst-report-published-on-august-4-2025-detailing-recent-pyrukynd-data-from-the-us-fda-adverse-event-reporting-system-co-is-committed-to-delivering-safe-effective-treatments-for-patients-with-rare-diseases-and-will-continue-to-follow-our-established-rigorous-pharmacovigilance-processes-separately-on-august-4-2025-the-saudi-food-and-drug-authority-announced-that-it-has-approvedpyrukynd
Agios Pharmaceuticals Says It Is Aware Of ...
08/04/2025 18:53:07

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
08/04/2025 17:06:36

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
08/04/2025 12:08:38

agios-pharmaceuticals-q2-eps-193-misses-177-estimate-sales-12455m-beat-9537m-estimate
Agios Pharmaceuticals Q2 EPS $(1.93) Misse...
07/31/2025 10:32:25

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

scotiabank-maintains-sector-outperform-on-agios-pharmaceuticals-lowers-price-target-to-65
Scotiabank Maintains Sector Outperform on ...
07/28/2025 21:29:26

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Outperform and lowers the price...

b-of-a-securities-maintains-buy-on-agios-pharmaceuticals-lowers-price-target-to-51
B of A Securities Maintains Buy on Agios P...
07/22/2025 16:15:51

B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target...

agios-avanmzanite-sign-agreement-for-pan-european-partnership-for-pyrukynd-launch
Agios, Avanmzanite Sign Agreement For Pan-...
06/09/2025 12:44:47

PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with P...

agios-pharma-new-data-on-pk-activators-mitapivat-and-tebapivat-to-be-featured-in-oral-and-poster-presentations-during-eha-congress-2025
Agios Pharma: New Data On PK Activators, M...
05/14/2025 14:02:10

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering thera...

scotiabank-maintains-sector-outperform-on-agios-pharmaceuticals-lowers-price-target-to-71
Scotiabank Maintains Sector Outperform on ...
05/02/2025 14:16:09

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Outperform and lowers the price...

agios-pharmaceuticals-q1-eps-155-beats-180-estimate-sales-873m-miss-964m-estimate
Agios Pharmaceuticals Q1 EPS $(1.55) Beats...
05/01/2025 10:34:40

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.55) per share which beat the analyst consensus estimate of...

Core News & Articles
Earnings Scheduled For May 1, 2025
05/01/2025 08:32:37

an-overview-of-agios-pharmaceuticalss-earnings
An Overview of Agios Pharmaceuticals's Ear...
04/30/2025 18:01:21

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION